人参皂苷Rb1在大鼠体内的药物代谢研究

人参皂苷Rb1是人参中的达玛烷型三萜皂苷类化合物, 具有多种生物活性. 对人参皂苷Rb1代谢产物的分析已有报道, 在大鼠尿液、粪便、胃和大肠中共检出了5种代谢产物. 本文采用高效液相色谱-飞行时间串联质谱进行人参皂苷Rb1的体内代谢研究, 通过口服和静脉给予药物, 在大鼠尿液中共检出了人参皂苷Rb1的14种代谢产物, 并系统分析和推断了这些代谢物的转化规律和可能结构.     

人参皂苷Rb2在大鼠体内的药代动力学行为及代谢产物研究

建立快速高分离度液相色谱-四极杆飞行时间质谱联用方法(RRLC-Q-TOF-MS),分析人参皂苷Rb2在大鼠体内的药代动力学行为,并探索人参皂苷Rb2在大鼠体内的代谢过程.采用Agilent SB-C18色谱柱,流动相A为0.1％甲酸溶液,B为乙腈,流速为0.2 mL/min,进样量为5μL,二元线性梯度洗脱分离,采用电喷雾负离子模式进行质谱检测.方法的检出限(S/N=3)和定量限(S/N=10)分别为0.08 μg/mL和0.1 μg/mL,线性范围为0.10～ 1.26 μg/mL.结果表明,人参皂苷Rb2静脉注射后的体内代谢过程符合二室模型特征,血药浓度半衰期的α相(t1/2α)和β相(t1/2β)分别为(23.58±1.10)和(1306.55±147.23) min.通过对静脉注射人参皂苷Rb2的大鼠尿液和口服后的粪便样本进行分析,发现Rb2的代谢产物为M6,M2(C-Y),F2,C-K.     

人参多糖对人参皂苷Re体内代谢和体外转化的影响

利用快速分离液相色谱-四极杆飞行时间质谱联用仪(RRLC/Q-TOF-MS)研究了人参多糖对肠道菌群转化人参皂苷Re的影响;考察了人参皂苷Re的代谢产物Rg1在口服人参多糖大鼠体内的药代动力学,并与正常大鼠体内Rg1的药代动力学参数进行了比较.结果表明,体外肠道菌群转化人参皂苷Re的主要转化产物有人参皂苷Rg1,Rh1,Rg2,F1和原人参三醇(Protopanaxatriol,PPT),分别归属于3条转化路径;正常情况下,肠道菌群转化人参皂苷Re 48 h时,除了终产物PPT的存在,中间产物Rg1,Rg2和F1仍可被检测到,而加入人参多糖后,只检测到终产物PPT.当口服给药Re后,代谢产物Rg1的达峰时间(tmax)、最大血浆浓度(cmax)和血浆药物浓度-时间曲线下面积(AUC)分别为(11.6±6.1) h,(80.1±44.0) ng/m L和(549.3±209.4) ng·h/m L;当给予人参多糖14 d后,口服给药Re,代谢产物Rg1的tmax,cmax和AUC分别为(8.2±5.4) h,(98.2±50.6) ng/m L和(691.9±231.2) ng·h/m L.研究结果表明,人参多糖能促进人参皂苷Re转化为人参皂苷Rg1,进而提高胃肠道对人参皂苷Rg1的吸收,并可能增强人参的药理作用.     

UPLC-TSQ-Endure质谱分析Rg_3对2型糖尿病大鼠P450酶活性的影响

应用超高效液相色谱-质谱联用法(UPLC-MS)结合多探针底物法建立了同时定量测定5个细胞色素P450酶探针底物的方法,同时考察正常大鼠和2型糖尿病大鼠CYP亚型酶活性的变化,分析人参皂苷Rg_3对CYP亚型酶的调控作用。结果表明,与正常组比较,2型糖尿病大鼠肝微粒体酶中P3A4和P2E1活性被诱导,P2D6,P1A2和P2C9活性被抑制。人参皂苷Rg_3诱导2型糖尿病大鼠P3A4和P1A2活性,抑制P2E1和P2C9活性,对P2D6活性无明显影响。人参皂苷Rg_3能够使糖尿病大鼠CYP2E1和CYP1A2亚型酶活性趋于恢复到正常生理状态,其在CYP450酶中的代谢产物为人参皂苷Rh2。方法适用于评价P450酶诱导或抑制的酶活性测定,在临床上指导2型糖尿病患者合理用药。     

人参皂苷Re在正常和中波紫外线辐射损伤模型大鼠体内药代动力学比较研究

建立了超高效液相色谱-三重四级杆质谱(UPLC-QQQ-MS)检测大鼠血浆中G-Re含量的方法,用于比较研究人参皂苷Re(Ginsenoside Re,G-Re)在正常大鼠和UVB辐射损伤模型大鼠体内的药代动力学行为。选用Ascentis~? Express C_(18)色谱柱(5.0 mm×3.0 mm,2.7μm),以0.1%甲酸-乙腈为流动相,梯度洗脱。电喷雾离子源(ESI)在负离子模式下,选择多反应监测模式(MRM)扫描,内标法定量,用于G-Re定量分析的离子为m/z 991.54/945.53/475.60。方法检出限为4.0 ng/m L,定量限为13.5 ng/m L,G-Re在15~20000 ng/m L范围内线性关系良好(r=0.999);日内和日间精密度、回收率、基质效应和稳定性均能满足药代动力学分析要求。结果表明,两组大鼠分别单次口服50 mg/kg G-Re后,体内代谢过程表现皆符合二室模型特征,正常组和模型组t_(1/2α)分别为(0.21±0.04)h和(0.69±0.07)h,t_(1/2β)分别为(17.08±0.53)h和(21.40±16.77)h,AUC_((0-t))分别为(321.91±2.27)"g/(L·h)和(474.99±194.96)"g/(L·h),AUC_((0-∞))分别为(332.44±1.66)"g/(L·h)和(518.64±231.39)"g/(L·h),除t_(1/2α)外,两组之间的药代动力学参数具有显著差异(p0.05)。本方法准确、灵敏、专属性强、稳定性好,可用于人参皂苷Re的体内药代动力学比较研究。     

尿液代谢组学方法研究人参总皂苷治疗糖尿病心肌病大鼠作用机制

利用基于质谱的代谢组学方法考察了人参总皂苷(TG)治疗糖尿病心肌病(DCM)大鼠的效应机制;建立了糖尿病心肌病大鼠模型,并连续12周口服人参总皂苷,采用快速高分辨液相色谱/四级杆-飞行时间/质谱(RRLC/Q-TOF/MS)技术对糖尿病心肌病模型组(DCM组)和人参总皂苷治疗组(TG组)大鼠尿样的尿液代谢物进行分析,采用主成分分析(PCA)对两组代谢物进行分类,并寻找潜在生物标记物,同时检测心肌病理超微结构、血液生化指标和心肌氧化应激水平。RRLC/Q-TOF/MS检测结果表明,DCM组和TG组大鼠的尿液代谢物谱能得到很好的区分,发现并鉴定了3种生物标记物。TG降低了DCM大鼠心肌超微结构损伤并改善其血脂、血糖及心肌氧化应激水平,代谢组学研究结果表明:作用机制可能是TG对柠檬酸循环、脂肪酸代谢和氧化应激水平的调节作用。     

LC-MS/MS法测定大鼠血浆中人参皂苷Rb1的含量及其药代动力学研究

采用液相色谱-串联质谱法快速、灵敏地测定大鼠血浆中人参皂苷Rb1(GRb1)的含量,并将该方法应用于大鼠口服GRb1后的代谢动力学研究。血浆样品采用96孔板进行液-液萃取后,应用Agilent SB-C18色谱柱(100 mm×2.1 mm,3.5μm)进行分离,以甲醇-0.1%甲酸溶液(体积比为75∶25)为流动相进行洗脱,在正离子模式下对GRb1和内标人参皂苷Rg1(GRg1)进行检测,用于定量的离子反应分别为1131.5→365.1(GRb1),823.3→643.4(GRg1)。人参皂苷Rb1血浆样品测定方法的定量线性范围为1~500 ng/mL,线性相关系数大于0.999,定量下限为1 ng/mL,批内和批间精密度(RSD)小于9.05%,回收率为79.7%~81.0%,基质效应为96.6%~99.3%。大鼠灌胃给予Rb15 mg/kg后,大鼠体内血药浓度到达高峰时间tmax为1.53 h,半衰期t1/2为13.54 h,药时曲线面积AUC0~72为16237.76(ng·h)/mL。该方法快速、高效、灵敏,适用于人参皂苷Rb1的代谢动力学研究。     

中药柴胡总皂苷急性肝毒性的代谢组学研究

运用UPLC-MS联用技术对空白对照组、柴胡总皂苷(SS)组大鼠在给药后第3天和第5天的尿液样本进行分析检测,获得了以质荷比和保留时间为变量的矩阵数据。据此建立各组大鼠的尿液代谢轮廓图,并利用主成分分析(PCA)建立了SS的代谢组学毒性模型。结合肝组织病理,探讨了柴胡总皂苷的急性肝毒性。对于SS组与正常组,大鼠尿液代谢轮廓图表现出了一定的差异。在代谢组学毒性模型中,给药第3天和第5天的PCA分类均偏离正常组,而第5天的偏离程度强于第3天。同时,在第5天的肝组织病理切片中发现了组织病变。由此表明,给药组大鼠的代谢组偏离了正常组,这种偏离正是肝急性毒性的表现,且给药到第5天的肝毒性强于第3天,表明肝毒性与给药累积剂量呈正相关,表现出了明显的急性和累积肝毒性。     

人参中人参皂苷的直接高压微波辅助降解

采用高效液相色谱-电喷雾质谱联用法测定了人参提取液中的人参皂苷. 考察了天然人参皂苷发生降解的条件, 同时研究了单体人参皂苷Rg1, Re, Rb1, Rc, Rb2和Rd的降解, 并对降解产物进行了分析. 结果表明, 随着提取压力的升高, 提取液中天然人参皂苷的含量逐渐减少, 同时产生多种次级人参皂苷. 当微波提取压力达到600 kPa, 提取时间为10 min时, 提取液中的主要天然人参皂苷达到完全降解, 次级人参皂苷Rg3含量达到最高. 在单体人参皂苷Rb1, Rc, Rb2和Rd的降解产物中均得到人参皂苷Rg3.     

动态泡沫浮选法分离富集人参提取液中的二醇型人参皂苷

采用动态泡沫浮选法分离富集人参提取液中的二醇型人参皂苷, 用高效液相色谱法测定6种人参皂苷Rg₁, Re, Rb₁, Rc, Rb₂和Rd的含量. 考察了浮选液pH值、电解质NaCl浓度、载气流量、料液浓度及料液流速对人参皂苷浮选率的影响, 确定了动态泡沫浮选的最佳条件, 并与溶剂提取法、溶剂浮选法以及静态泡沫浮选法进行了比较. 结果表明, 动态泡沫浮选法对二醇型人参皂苷Rb₁, Rc, Rb₂和Rd具有高富集效率, 回收率分别为93.3%, 98.6%, 96.9%和98.3%, 而对三醇型人参皂苷Rg1和Re的富集效率却很低, 回收率分别为4.8%和4.2%. 该法是分离纯化二醇型人参皂苷的一种简便有效的方法.     

Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2

In vivo metabolism and pharmacokinetic studies on rat were conducted for ginsenoside Rh2, one of the components from ginseng that shows promise of anticancer activity. Liquid chromatography/mass spectrometry (LC/MS) and tandem mass spectrometry (MS/MS) with electrospray ionization were used to determine Rh2 and its metabolites in rat plasma, urine and feces. An average half-life of 16 min in plasma was obtained after intravenous administration to male Sprague-Dawley rats at 5 mg/kg. No Rh2 was detected in plasma samples collected from 0 to 24 h following oral administration at 100 mg/kg, and only 0.12-0.25% of the dosed amount was found in the feces samples collected from 0 to 48 h after oral administration at 100 mg/kg. Three metabolites of Rh2 were detected in the feces samples. Oxygenation and deglycosylation were found to be the major metabolic pathways of Rh2. Intense metabolism, rather than excretion, appears to be the reason for the fast clearance of this ginsenoside.     

Comparative analysis of absorbed ingredients and metabolites,and pharmacokinetic studies of Zhimu–Huangbai herb pair in the plasma of normal and type 2 diabetes mellitus rats by UHPLC-linear trap quadrupole-orbitrap MS and LC-MS/MS

A new rapid ultra-high-performance liquid chromatography coupled with linear trap quadrupole orbitrap mass spectrometry method was established for the qualitative analysis of absorbed ingredients and metabolites of Zhimu–Huangbai herb pair, which is used to treat type 2 diabetes mellitus. A total of 16 absorbed ingredients and 11 metabolites were identified in normal and type 2 diabetes mellitus rats, respectively. Such findings indicated that the diabetic model had no effect on the type of components in plasma. Seven absorbed ingredients and 11 metabolites were first identified after the oral administration of Zhimu–Huangbai herb pair. Thereafter, ultra-high-performance liquid chromatography coupled with linear trap quadrupole orbitrap mass spectrometry and liquid chromatography-API4000⁺ triple quadrupole mass spectrometer methods were established and validated for pharmacokinetic comparative studies of seven major bioactive components in normal and type 2 diabetes mellitus rats. Partial pharmacokinetic parameters in the plasma of type 2 diabetes mellitus rats were significantly different from those in normal rats. To our knowledge, this is the first comparison of absorbed ingredients and metabolites of Zhimu–Huangbai herb pair, and its use in pharmacokinetic studies between normal and type 2 diabetes mellitus rats. Ultimately, our findings provide insights into the clinical usage of Zhimu–Huangbai herb pair.     

Major ginsenoside contents in rhizomes of Panax sokpayensis and Panax bipinnatifidus

This study compared eight major ginsenosides (Rg1, Rg2, Rf, Re, Rd, Rc, Rb1 and Rb2) between Panax sokpayensis and Panax bipinnatifidus collected from Sikkim Himalaya, India. High-performance liquid chromatographic analysis revealed that all major ginsenosides were present in the rhizomes of P. sokpayensis except ginsenoside Rc, whereas ginsenoside Rf, Rc and Rb2 were not detected in P. bipinnatifidus.     

The effectiveness of borneol on pharmacokinetics changes of four ginsenosides in Shexiang Baoxin Pill in vivo

Shexiang Baoxin Pill (SBP) is a traditional Chinese medicine, widely used for cardiovascular diseases in the clinic. Ginsenosides are important effective components in SBP, but their pharmacokinetic characteristics are still not known. In this paper, we studied the pharmacokinetics of ginsenoside Rb1, Rc, Re and Rg1 in SBP and investigated the effect of borneol on the pharmacokinetic characteristic of ginsenosides based on an Agilent G6410A triple quadrupole LC/MS system. Results showed that the pharmacokinetic parameters of ginsenoside Rb1, Rc, Re and Rg1 in rat plasma after oral administration of SBP are significantly different with oral administration of SBP without Borneolum Syntheticum. Plasma pharmacokinetic profiles after oral administration of ginsenoside Rb1, Rc, Re, Rg1 and co‐administration with borneol at three different ratios (10:1, 1:1 and 1:10 ginsenoside vs borneol, w/w) were also determined. It was demonstrated that borneol can elevate the plasma concentration of ginsenosides after co‐admininstration. Copyright © 2013 John Wiley & Sons, Ltd.     

Studies on Intestinal Transport of Ginsenoside Compatibility with Veratrum nigrum via Caco-2 Cell Monolayer Model Coupled with UPLC-ESI-MS Method

The Caco-2 cells have been recognized as effective tools to be applied to imitating the drug absorption in human intestine for the transport of drug. Herein, Caco-2 cell monolayer model was used to study the transport of the ginsenoside compatibility with Veratrum nigrum in different proportions. A specific high performance liquid chromatography-electrospray ionization-mass spectrometry(HPLC-ESI-MS) method was developed for the semiquantitative determination of ginsenoside in intestinal transport with Dioscin as an internal standard. For the Caco-2 model constructed, two influencing factors were investigated, including time and concentration. The results suggest that the absorption of ginsenoside Re, Rg1, Rb1, Rc, Rb2 and Rd are time- and concentration-dependent and the excretions of Rb1, Rc, Rb2 and Rd have a relatronship with some transport proteins. The bioavailability of the ginsenosides has reduced compared to the single Panax ginseng extract when compatibility with a certain amount of Veratrum nigrum.     

Production of Minor Ginsenosides C-K and C-Y from Naturally Occurring Major Ginsenosides Using Crude β-Glucosidase Preparation from Submerged Culture of Fomitella fraxinea

Minor ginsenosides, such as compounds (C)-K and C-Y, possess relatively better bioactivity than those of naturally occurring major ginsenosides. Therefore, this study focused on the biotransformation of major ginsenosides into minor ginsenosides using crude β-glucosidase preparation isolated from submerged liquid culture of Fomitella fraxinea (FFEP). FFEP was prepared by ammonium sulfate (30–80%) precipitation from submerged culture of F. fraxinea. FFEP was used to prepare minor ginsenosides from protopanaxadiol (PPD)-type ginsenoside (PPDG-F) or total ginsenoside fraction (TG-F). In addition, biotransformation of major ginsenosides into minor ginsenosides as affected by reaction time and pH were investigated by TLC and HPLC analyses, and the metabolites were also identified by UPLC/negative-ESI-Q-TOF-MS analysis. FFEP biotransformed ginsenosides Rb1 and Rc into C-K via the following pathways: Rd → F2 → C-K for Rb1 and both Rd → F2→ C-K and C-Mc1 → C-Mc → C-K for Rc, respectively, while C-Y is formed from Rb2 via C-O. FFEP can be applied to produce minor ginsenosides C-K and C-Y from PPDG-F or TG-F. To the best of our knowledge, this study is the first to report the production of C-K and C-Y from major ginsenosides by basidiomycete F. fraxinea.     

UHPLC-MS-Based Serum and Urine Metabolomics Reveals the Anti-Diabetic Mechanism of Ginsenoside Re in Type 2 Diabetic Rats

Panax ginseng was employed in the treatment of “Xiao-Ke” symptom, which nowadays known as diabetes mellitus, in traditional Chinese medicine for more than a thousand years. Ginsenoside Re was the major pharmacologic ingredient found abundantly in ginseng. However, the anti-diabetic of Ginsenoside Re and its underlying mechanism in metabolic level are still unclear. Serum and urine metabolomic method was carried out to investigate the anti-diabetic pharmacological effects and the potential mechanism of Ginsenoside Re on high-fat diet combined streptozotocin-induced type 2 diabetes mellitus (T2DM) rats based on ultra-high-performance liquid chromatography coupled with quadrupole exactive orbitrap mass spectrometry (UHPLC-Q-Exactive Orbitrap/MS). Serum and urine samples were collected from the control group (CON), T2DM group, metformin (MET) treatment group, and ginsenoside Re treatment group after intervention. The biochemical parameters of serum were firstly analyzed. The endogenous metabolites in serum and urine were detected by UHPLC-MS. The potential metabolites were screened by multivariate statistical analysis and identified by accurate mass measurement, MS/MS, and metabolite databases. The anti-diabetic-related metabolites were analyzed by KEGG metabolic pathway, and its potential mechanism was discussed. The treatment of ginsenoside Re significantly reduced the blood glucose and serum lipid level improved the oxidative stress caused by T2DM. Biochemical parameters (urea nitrogen, uric acid) showed that ginsenoside Re could improve renal function in T2DM rats. Respective 2 and 6 differential metabolites were found and identified in serum and urine of ginsenoside Re compared with T2DM group and enriched in KEGG pathway. Metabolic pathways analysis indicated that the differential metabolites related to T2DM were mainly involved in arachidonic acid metabolism, Vitamin B6, steroid hormone biosynthesis, and bile secretion metabolic pathways. This study verified the anti-diabetic and anti-oxidation effects of ginsenoside Re, elaborated that ginsenoside Re has a good regulation of the metabolic disorder in T2DM rats, which could promote insulin secretion, stimulated cannabinoid type 1 receptor (CB₁), and CaMKK β to activate AMPK signaling pathway, inhibited insulin resistance, and improved blood glucose uptake and diabetic nephropathy, so as to play the role of anti-diabetic.     

HPLC-MS结合多元统计分析区分人参产地及筛选皂苷类标志物

利用高效液相色谱-质谱联用(HPLC-MS)技术结合多元统计分析方法, 区分中国人参主产区5个不同产地的45个人参样本, 筛选出差异性皂苷类标志物. 根据人参总皂苷在反相C₁₈色谱柱中的洗脱顺序, 结合串联质谱分析和标准品比对, 在提取的人参总皂苷中鉴定出15种原人参三醇型、 24种原人参二醇型和2种齐墩果酸型共41种皂苷. 对人参总皂苷的HPLC-MS全扫描数据进行了多元统计分析. 正交偏最小二乘-判别分析(OPLS-DA)结果表明, 所建立的分析模型具有良好的数据描述能力和预测能力. 所有人参样本能够根据产地被区分, 并筛选得到同时区分5个产地的差异性皂苷类组分18种; 能够区分任意2个产地人参样本的差异性组分主要为在人参中含量较高的人参皂苷Rb1, Rg1, Re, Rc, Rd, Ro和m-Rb1等. 分层聚类分析(HCA)结果显示, 黑龙江和吉林两省的样本能够独自聚类, 但是绥化市的样本更接近于吉林省. 初步推断原因为绥化市地理位置较接近吉林省, 两地人参生长环境相似并可能存在种质资源交换.     

Purification and characterization of new special ginsenosidase hydrolyzing multi-glycisides of protopanaxadiol ginsenosides, ginsenosidase type I

In this paper, the new type ginsenosidase which hydrolyzing multi-glycosides of ginsenoside, named ginsenoside type I from Aspergillus sp.g48p strain was isolated, characterized and generally described. The enzyme molecular weight was about 80 kDa. Ginsenosidase type I can hydrolyze different glycoside of protopanaxadiol type ginsenosides (PPD); i.e., can hydrolyze the 3(carbon)-O-beta-glucoside of Rb1, Rb2, Rb3, Rc, Rd; can hydrolyze 20(carbon)-O-beta-glucoside of Rb1, 20-O-beta-xyloside of Rb3, 20-O-alpha-arabinoside(p) of Rb2 and 20-O-alpha-arabinoside(f) of Rc to produce mainly F2, compound-K (C-K) and small Rh2, but can not hydrolyze the glycosides of protopanaxatriol type ginsenoside (PPT) such as Re, Rf, Rg1. So, when the ginsenosidase type I hydrolyzed ginsenosides, the enzyme selected ginsenoside-aglycone type, can hydrolyze different glycosides of PPD type ginsenoside; however no selected glycoside type, can hydrolyze multi-glycosides of PPD type ginsenosides. These properties were novel properties, and differentiated with the other previously described glycosidases.